Efficacy of an accelerated hepatitis b vaccination program during pregnancy

Jeanne S. Sheffield, Ashley Hickman, Jennifer Tang, Kristie Moss, Atoosa KouroS.H., Natalie M. Crawford, George D. Wendel

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: To estimate the feasibility and immunogenicity of an accelerated hepatitis B vaccination schedule of 0, 1, and 4 months in high-risk pregnant women. Methods:We conducted a prospective clinical trial of high-risk pregnant women who were hepatitis B surface antigen-negative at presentation for prenatal care. A detailed questionnaire was administered and eligible women received a hepatitis B vaccine intramuscularly on a 0-, 1-, and 4-month schedule. Adverse reactions and hepatitis B surface antigen seroconversion rates were documented. Factors influencing seroconversion were determined. Rssults: Two hundred high-risk pregnant women were enrolled; 84% completed the three-dose vaccine series. Seroconversion (hepatitis B surface antigen 10 milli-international units/mL or greater) after one dose was 56% (95% confidence interval [CI], 49-63%), 77% (95% CI, 71-83%) after two doses, and 90% (95% CI, 85-94%) after completing three doses. Body mass index was inversely associated with seroconversion rates (P<.001). There was no single body mass index above which seroconversion did not occur. There were no serious adverse events; injection site discomfort was the most prevalent complaint (10.5%). CONCLUSION:: An accelerated hepatitis B vaccination schedule at 0, 1, and 4 months in high-risk pregnant women is effective, practical, and well tolerated. This accelerated vaccine strategy can be completed during the course of pregnancy and provides another means of decreasing hepatitis B virus disease and transmission.

Original languageEnglish (US)
Pages (from-to)1130-1135
Number of pages6
JournalObstetrics and Gynecology
Volume117
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

Hepatitis
Vaccination
Pregnant Women
Pregnancy
Hepatitis B Surface Antigens
Appointments and Schedules
Confidence Intervals
Hepatitis B
Body Mass Index
Vaccines
Hepatitis B Vaccines
Prenatal Care
Virus Diseases
Hepatitis B virus
Seroconversion
Clinical Trials
Injections

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Sheffield, J. S., Hickman, A., Tang, J., Moss, K., KouroS.H., A., Crawford, N. M., & Wendel, G. D. (2011). Efficacy of an accelerated hepatitis b vaccination program during pregnancy. Obstetrics and Gynecology, 117(5), 1130-1135. https://doi.org/10.1097/AOG.0b013e3182148efe

Efficacy of an accelerated hepatitis b vaccination program during pregnancy. / Sheffield, Jeanne S.; Hickman, Ashley; Tang, Jennifer; Moss, Kristie; KouroS.H., Atoosa; Crawford, Natalie M.; Wendel, George D.

In: Obstetrics and Gynecology, Vol. 117, No. 5, 05.2011, p. 1130-1135.

Research output: Contribution to journalArticle

Sheffield, JS, Hickman, A, Tang, J, Moss, K, KouroS.H., A, Crawford, NM & Wendel, GD 2011, 'Efficacy of an accelerated hepatitis b vaccination program during pregnancy', Obstetrics and Gynecology, vol. 117, no. 5, pp. 1130-1135. https://doi.org/10.1097/AOG.0b013e3182148efe
Sheffield, Jeanne S. ; Hickman, Ashley ; Tang, Jennifer ; Moss, Kristie ; KouroS.H., Atoosa ; Crawford, Natalie M. ; Wendel, George D. / Efficacy of an accelerated hepatitis b vaccination program during pregnancy. In: Obstetrics and Gynecology. 2011 ; Vol. 117, No. 5. pp. 1130-1135.
@article{cc1fd8a49a4047c49b8e7efa7f385112,
title = "Efficacy of an accelerated hepatitis b vaccination program during pregnancy",
abstract = "Objective: To estimate the feasibility and immunogenicity of an accelerated hepatitis B vaccination schedule of 0, 1, and 4 months in high-risk pregnant women. Methods:We conducted a prospective clinical trial of high-risk pregnant women who were hepatitis B surface antigen-negative at presentation for prenatal care. A detailed questionnaire was administered and eligible women received a hepatitis B vaccine intramuscularly on a 0-, 1-, and 4-month schedule. Adverse reactions and hepatitis B surface antigen seroconversion rates were documented. Factors influencing seroconversion were determined. Rssults: Two hundred high-risk pregnant women were enrolled; 84{\%} completed the three-dose vaccine series. Seroconversion (hepatitis B surface antigen 10 milli-international units/mL or greater) after one dose was 56{\%} (95{\%} confidence interval [CI], 49-63{\%}), 77{\%} (95{\%} CI, 71-83{\%}) after two doses, and 90{\%} (95{\%} CI, 85-94{\%}) after completing three doses. Body mass index was inversely associated with seroconversion rates (P<.001). There was no single body mass index above which seroconversion did not occur. There were no serious adverse events; injection site discomfort was the most prevalent complaint (10.5{\%}). CONCLUSION:: An accelerated hepatitis B vaccination schedule at 0, 1, and 4 months in high-risk pregnant women is effective, practical, and well tolerated. This accelerated vaccine strategy can be completed during the course of pregnancy and provides another means of decreasing hepatitis B virus disease and transmission.",
author = "Sheffield, {Jeanne S.} and Ashley Hickman and Jennifer Tang and Kristie Moss and Atoosa KouroS.H. and Crawford, {Natalie M.} and Wendel, {George D.}",
year = "2011",
month = "5",
doi = "10.1097/AOG.0b013e3182148efe",
language = "English (US)",
volume = "117",
pages = "1130--1135",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Efficacy of an accelerated hepatitis b vaccination program during pregnancy

AU - Sheffield, Jeanne S.

AU - Hickman, Ashley

AU - Tang, Jennifer

AU - Moss, Kristie

AU - KouroS.H., Atoosa

AU - Crawford, Natalie M.

AU - Wendel, George D.

PY - 2011/5

Y1 - 2011/5

N2 - Objective: To estimate the feasibility and immunogenicity of an accelerated hepatitis B vaccination schedule of 0, 1, and 4 months in high-risk pregnant women. Methods:We conducted a prospective clinical trial of high-risk pregnant women who were hepatitis B surface antigen-negative at presentation for prenatal care. A detailed questionnaire was administered and eligible women received a hepatitis B vaccine intramuscularly on a 0-, 1-, and 4-month schedule. Adverse reactions and hepatitis B surface antigen seroconversion rates were documented. Factors influencing seroconversion were determined. Rssults: Two hundred high-risk pregnant women were enrolled; 84% completed the three-dose vaccine series. Seroconversion (hepatitis B surface antigen 10 milli-international units/mL or greater) after one dose was 56% (95% confidence interval [CI], 49-63%), 77% (95% CI, 71-83%) after two doses, and 90% (95% CI, 85-94%) after completing three doses. Body mass index was inversely associated with seroconversion rates (P<.001). There was no single body mass index above which seroconversion did not occur. There were no serious adverse events; injection site discomfort was the most prevalent complaint (10.5%). CONCLUSION:: An accelerated hepatitis B vaccination schedule at 0, 1, and 4 months in high-risk pregnant women is effective, practical, and well tolerated. This accelerated vaccine strategy can be completed during the course of pregnancy and provides another means of decreasing hepatitis B virus disease and transmission.

AB - Objective: To estimate the feasibility and immunogenicity of an accelerated hepatitis B vaccination schedule of 0, 1, and 4 months in high-risk pregnant women. Methods:We conducted a prospective clinical trial of high-risk pregnant women who were hepatitis B surface antigen-negative at presentation for prenatal care. A detailed questionnaire was administered and eligible women received a hepatitis B vaccine intramuscularly on a 0-, 1-, and 4-month schedule. Adverse reactions and hepatitis B surface antigen seroconversion rates were documented. Factors influencing seroconversion were determined. Rssults: Two hundred high-risk pregnant women were enrolled; 84% completed the three-dose vaccine series. Seroconversion (hepatitis B surface antigen 10 milli-international units/mL or greater) after one dose was 56% (95% confidence interval [CI], 49-63%), 77% (95% CI, 71-83%) after two doses, and 90% (95% CI, 85-94%) after completing three doses. Body mass index was inversely associated with seroconversion rates (P<.001). There was no single body mass index above which seroconversion did not occur. There were no serious adverse events; injection site discomfort was the most prevalent complaint (10.5%). CONCLUSION:: An accelerated hepatitis B vaccination schedule at 0, 1, and 4 months in high-risk pregnant women is effective, practical, and well tolerated. This accelerated vaccine strategy can be completed during the course of pregnancy and provides another means of decreasing hepatitis B virus disease and transmission.

UR - http://www.scopus.com/inward/record.url?scp=79955529541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955529541&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e3182148efe

DO - 10.1097/AOG.0b013e3182148efe

M3 - Article

C2 - 21508752

AN - SCOPUS:79955529541

VL - 117

SP - 1130

EP - 1135

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 5

ER -